Abstract
The in vitro antibacterial activity of the new carbapenem antibiotic meropenem (SM-7338) against 567 clinical isolates was evaluated. SM-7338 exhibited activity against a broad spectrum of organisms, including aerobes and anaerobes, and was superior to the other beta-lactam drugs tested (piperacillin, cefotaxime, ceftazidime, ceftriaxone, cefoxitin). SM-7338 was more active than imipenem, gentamicin and amikacin againstEnterobacter cloacae andPseudomonas aeruginosa. SM-7338 was less potent than imipenem against staphylococci and enterococci, but the activity of the two antibiotics against anaerobes was similar. SM-7338 and imipenem showed a high bactericidal activity at a concentration of 2–4 x MIC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Edwards, J. R., Turner, P. J., Wannop, C., Withnell, E. S., Grindey, A. J., Nari, K. In vitro antimicrobial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I. Antimicrobial Agents and Chemotherapy 1989, 33: 215–222.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ravizzola, G., Pinsi, G., Gonzales, R. et al. Antibacterial activity of the new carbapenem meropenem (SM-7338) against clinical isolates. Eur. J. Clin. Microbiol. Infect. Dis. 8, 1053–1061 (1989). https://doi.org/10.1007/BF01975169
Issue Date:
DOI: https://doi.org/10.1007/BF01975169